BIIB Stock Price Today (October 2026) — Biogen Inc. Analysis & Key Metrics 2026-10-07
Biogen Inc. (BIIB) is trading at $222.15, down 0.33% today (as of October 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $238.18 (7.2% upside).
- Volatility is low (17.24% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: steady revenue (3.40% YoY) alongside competitive pressures in the Drug Manufacturers - General space.
BIIB Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Biogen Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $39.89B
P/E Ratio
Forward P/E: 13.10
Revenue Growth
Year over Year
Analyst Target
+7.2% upside potential
Key Investor Questions About BIIB
What investors need to know before buying
Based on current market data, BIIB presents a neutral technical setup with mixed signals fundamentals.
- Technicals say: Neutral (RSI 51.14)
- Fundamentals say: Mixed signals (nuanced financial profile)
BIIB's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for BIIB investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $8.36B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, BIIB stock traded between $138.00 and $230.49 and currently trades near the high end of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 17.24% annualized volatility and β=0.49, the stock exhibits low sensitivity to market moves—making BIIB suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Biogen (NASDAQ:BIIB) and its peers.
How Investors May Respond To Biogen (BIIB) Advancing At-Home LEQEMBI Pen And Kidney Disease Data
Earlier this month, Eisai and Biogen secured Japanese approval for the at-home LEQEMBI Pen subcutaneous formulation for early Alzheimer’s disease, while Biogen also published Phase 3 VALIANT adolescent subgroup data showing EMPAVELI improved proteinuria and stabilized kidney function in rare complement-mediated kidney disorders. Together, these updates highlight Biogen’s push to make complex therapies more accessible in real-world settings, potentially broadening treatment reach in both...
Biogen (BIIB) Posts New Kidney Trial Data, Is It Still 5% Undervalued?
Biogen (BIIB) is back in focus after publishing adolescent subgroup data from its Phase 3 VALIANT trial of EMPAVELI in rare kidney diseases, a catalyst that gives investors fresh clinical context around the stock. For context, Biogen’s recent clinical and product news has landed against a backdrop of stronger trading action, with a 1-day share price return of 2.87% on the latest close at US$225.36 and a 90-day share price return of 12.91%. Investors are weighing kidney and Alzheimer’s updates...
Is Biogen Stock Outperforming the S&P 500?
Biogen has outpaced the broader S&P 500 Index over the past year, and analysts remain reasonably upbeat about the stock’s prospects.
Biogen (BIIB) and AbbVie (ABBV) Get Wolfe Upgrades—Which Pharma Stock Has More Upside?
Wolfe Research upgraded two prominent pharmaceutical companies to Outperform on August 13. The firm upgraded both Biogen Inc. (NASDAQ:BIIB) and AbbVie Inc. (NYSE:ABBV)’s ratings from Peer Perform, with Wolfe assigning them similar $300 price targets. The firm’s logic in each case was based on a comparable set of factors: pipelines that the market appears to […]
Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience
Biogen (NASDAQ:BIIB) is reshaping its business around a broader mix of neuroscience, immunology, kidney disease and ophthalmology assets, President and CEO Chris Viehbacher said during a Morgan Stanley event. The company expects a series of late-stage clinical readouts to begin as soon as next quart
Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology
Biogen (NASDAQ:BIIB) executives said the company is focused on diversifying beyond its historical neurology concentration, advancing a broader late-stage pipeline and managing expenses as it seeks to return to growth. Speaking at a Wells Fargo conference, Chief Financial Officer Robin Kramer said B
This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging.
Ionis Pharmaceuticals wins regulatory clearance for its quarterly injection, Zanvastro, in Alexander disease. Analysts are focused elsewhere.
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Veeva Systems (VEEV) Winning Big In AI For Biopharma?
Veeva Systems (NYSE: VEEV) announced that Regeneron and Biogen have adopted its AI powered Vault CRM suite globally. The company also introduced Veeva Falcon Safety, a new agentic safety operations product for biopharma clients. Both moves expand Veeva Systems' AI focused offering across commercial and safety workflows in life sciences. These updates highlight how AI heavy software is becoming core infrastructure for healthcare and biopharma workflows. This connects directly to a wider set...
Explore More Analysis for BIIB
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Oct 28, 2026 (before the open, usually)
Frequently Asked Questions
Common investor questions about Biogen Inc.
Biogen Inc. (BIIB) is currently trading at $222.15. The RSI (14-day) is at 51.1, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $238.18 implies 7.2% upside from current levels. Volatility is low at 17.2% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Biogen Inc. (BIIB): The trailing P/E ratio is 38.88, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 13.10, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.56, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 1.70. Price-to-Sales is 3.20. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 31 analysts covering BIIB, the consensus price target is $238.18. This represents a 7.2% upside from the current price of $222.15. The range spans from a low target of $175.00 to a high target of $300.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Biogen Inc. (BIIB) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Biogen Inc. (BIIB) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Biogen Inc.'s (BIIB) current debt and financial health profile: Total debt stands at $8.36B. The debt-to-equity ratio is 0.44x, which is moderate and generally manageable for most companies. The current ratio is 1.87, indicating strong short-term liquidity. The quick ratio is 0.94. The company holds $1.28B in cash and equivalents. Free cash flow is positive at $1.27B, providing a cushion for debt servicing and shareholder returns.